Please assess the completion status of the following clinical trial:

Trial Title: Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject.~* A male or female between, and including, 18 and 40 years of age at the time of the first vaccination.~* Healthy subjects as established by medical history, physical examination and laboratory assessment before entering into the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.~* Planned administration/administration of a vaccine/product not foreseen by the study protocol in the period starting 30 days before the first vaccine dose and ending 30 days after the last dose of vaccines.~* Previous vaccination with a vaccine containing NTHi antigens.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose, or equivalent. Topical steroids are allowed.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccines or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Laboratory evidence of clinically significant haematological (complete blood cell count \[Red Blood Cells (RBC), White Blood Cells (WBC)\], WBC differential count, platelets count and haemoglobin level) and biochemical (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], creatinine and lactate dehydrogenase \[LDH\]) abnormalities as per the opinion of the investigator based on the local laboratory normative data.~* Acute disease and/or fever at the time of enrolment.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* History of or current condition preventing intramuscular injection as bleeding or coagulation disorder.~* Malignancies within previous 5 years (excluding non-melanic skin cancer) and lymphoproliferative disorders.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of chronic alcohol consumption and/or drug abuse.~* Any other condition that the investigator judges may interfere with study findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
- Group B (Type: PLACEBO_COMPARATOR): Subjects in this group will receive placebo in Step 1 of the study
- Group C (Type: EXPERIMENTAL): Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
- Group D (Type: PLACEBO_COMPARATOR): Subjects in this group will receive placebo in Step 2 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete